Made in China heart drug has been recalled across the country for presence of contaminant N-nitrosodimethylamine
In the latest medical safety scandal to hit China, the National Health Commission (NHC) has asked all medical institutions to stop using medicines containing the active ingredient valsartan produced by a domestic pharmaceutical company and to assist with related recalls.
The recall is due to an impurity involving the contaminant N-nitrosodimethylamine (NDMA), which was detected in the active pharmaceutical ingredients for valsartan, used to treat high blood pressure and heart failure. NDMA has been linked to cancer.
Medical institutions must not use the recalled drugs containing impurity-affected valsartan during diagnosis and treatment, said a statement by the NHC, which added that medical personnel should take efficient measures to ensure medical safety.
The statement also asked medical institutions to keep local medical authorities and regulators informed about their work on assisting with the recall and halting use of the recalled drugs.
The producer, Zhejiang Huahai Pharmaceutical Co. Ltd., halted shipments and launched voluntary recalls in domestic and foreign markets after it reported discovery of NDMA traces in its products for export to the drug regulator on 6 July 2018.
Click here for the complete issue.